These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 22230331)

  • 1. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation.
    Nicholson SC; Welte T; File TM; Strauss RS; Michiels B; Kaul P; Balis D; Arbit D; Amsler K; Noel GJ
    Int J Antimicrob Agents; 2012 Mar; 39(3):240-6. PubMed ID: 22230331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.
    Awad SS; Rodriguez AH; Chuang YC; Marjanek Z; Pareigis AJ; Reis G; Scheeren TW; Sánchez AS; Zhou X; Saulay M; Engelhardt M
    Clin Infect Dis; 2014 Jul; 59(1):51-61. PubMed ID: 24723282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
    File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA;
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
    Low DE; File TM; Eckburg PB; Talbot GH; David Friedland H; Lee J; Llorens L; Critchley IA; Thye DA;
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii33-44. PubMed ID: 21482568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.
    Syed YY
    Drugs; 2014 Sep; 74(13):1523-42. PubMed ID: 25117196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftobiprole for the treatment of pneumonia: a European perspective.
    Liapikou A; Cillóniz C; Torres A
    Drug Des Devel Ther; 2015; 9():4565-72. PubMed ID: 26316697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia.
    San Pedro GS; Cammarata SK; Oliphant TH; Todisco T;
    Scand J Infect Dis; 2002; 34(10):720-8. PubMed ID: 12477321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials.
    Scheeren TWL; Welte T; Saulay M; Engelhardt M; Santerre-Henriksen A; Hamed K
    BMC Infect Dis; 2019 Feb; 19(1):195. PubMed ID: 30808293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
    Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
    Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
    Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
    Critchley IA; Eckburg PB; Jandourek A; Biek D; Friedland HD; Thye DA
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii45-51. PubMed ID: 21482569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftobiprole medocaril for the treatment of community-acquired pneumonia.
    Falcó V; Burgos J; Almirante B
    Expert Opin Pharmacother; 2018 Sep; 19(13):1503-1509. PubMed ID: 30198789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
    Pertel PE; Bernardo P; Fogarty C; Matthews P; Northland R; Benvenuto M; Thorne GM; Luperchio SA; Arbeit RD; Alder J
    Clin Infect Dis; 2008 Apr; 46(8):1142-51. PubMed ID: 18444848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy.
    DiMondi VP; Drew RH; Chen LF
    Expert Rev Anti Infect Ther; 2011 Aug; 9(8):567-72. PubMed ID: 21819323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
    File TM; Segreti J; Dunbar L; Player R; Kohler R; Williams RR; Kojak C; Rubin A
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1965-72. PubMed ID: 9303395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
    Ortiz-Ruiz G; Vetter N; Isaacs R; Carides A; Woods GL; Friedland I
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii59-66. PubMed ID: 15150184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
    Noel GJ; Bush K; Bagchi P; Ianus J; Strauss RS
    Clin Infect Dis; 2008 Mar; 46(5):647-55. PubMed ID: 18225981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
    Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F
    Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients.
    Bosheva M; Gujabidze R; Károly É; Nemeth A; Saulay M; Smart JI; Hamed KA
    Pediatr Infect Dis J; 2021 Jun; 40(6):e222-e229. PubMed ID: 33480665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia.
    Scheeren TW
    Future Microbiol; 2015; 10(12):1913-28. PubMed ID: 26573022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.